LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)

Authors :: M. Dirnberger‐Hertweck
Anna Marina Liberati
Tobias Menne
Aleš Obr
Wojciech Jurczak
Gilles Salles
Kami J. Maddocks
Sumeet Ambarkhane
Gianluca Gaidano
Johannes Duell
Marc André
Pau Abrisqueta
Johannes Weirather
M. Dreyling
Eva González-Barca
Source :: Hematological Oncology. 39
Publication Year :: 2021
Publisher :: Wiley, 2021.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Phases of clinical research
Hematology
General Medicine
Internal medicine
Medicine
Refractory Diffuse Large B-Cell Lymphoma
In patient
business
Lenalidomide
medicine.drug

Full Text Access

Tools